Comparator: exenatide + Comparator: exenatide + Comparator: Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
The Methodology Assessment of Glucose Dependent Insulin Secretion
Conditions
The Methodology Assessment of Glucose Dependent Insulin Secretion
Trial Timeline
Sep 1, 2008 → Mar 1, 2009
NCT ID
NCT00782418About Comparator: exenatide + Comparator: exenatide + Comparator: Placebo
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo is a phase 1 stage product being developed by Merck for The Methodology Assessment of Glucose Dependent Insulin Secretion. The current trial status is completed. This product is registered under clinical trial identifier NCT00782418. Target conditions include The Methodology Assessment of Glucose Dependent Insulin Secretion.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00782418 | Phase 1 | Completed |
Competing Products
1 competing product in The Methodology Assessment of Glucose Dependent Insulin Secretion
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| placebo + zolpidem + zolpidem | Pfizer | Phase 1 | 32 |